These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33502080)

  • 1. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.
    Rodríguez Rodríguez M; Castro Quismondo N; Zafra Torres D; Gil Alos D; Ayala R; Martinez-Lopez J
    Int J Lab Hematol; 2021 Aug; 43(4):O152-O155. PubMed ID: 33502080
    [No Abstract]   [Full Text] [Related]  

  • 2. ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.
    Henry BM; Benoit SW; de Oliveira MHS; Lippi G; Favaloro EJ; Benoit JL
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1(Suppl 1):129-136. PubMed ID: 33270980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.
    Marco A; Marco P
    J Thromb Thrombolysis; 2021 Aug; 52(2):497-503. PubMed ID: 33866481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients.
    Delrue M; Siguret V; Neuwirth M; Joly B; Beranger N; Sène D; Chousterman BG; Voicu S; Bonnin P; Mégarbane B; Stépanian A
    Br J Haematol; 2021 Mar; 192(6):1097-1100. PubMed ID: 33368196
    [No Abstract]   [Full Text] [Related]  

  • 5. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.
    Grandone E; Vimercati A; Sorrentino F; Colaizzo D; Ostuni A; Ceci O; Capozza M; Tiscia G; De Laurenzo A; Mastroianno M; Cappucci F; Fischetti L; Margaglione M; Cicinelli E; Nappi L
    BMC Pregnancy Childbirth; 2022 Feb; 22(1):142. PubMed ID: 35189860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.
    Seth R; McKinnon TAJ; Zhang XF
    Am J Physiol Heart Circ Physiol; 2022 Jan; 322(1):H87-H93. PubMed ID: 34890277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients.
    Martín-Rojas RM; Chasco-Ganuza M; Casanova-Prieto S; Delgado-Pinos VE; Pérez-Rus G; Duque-González P; Sancho M; Díez-Martín JL; Pascual-Izquierdo C
    Blood Coagul Fibrinolysis; 2021 Oct; 32(7):458-467. PubMed ID: 34310402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019.
    Doevelaar AAN; Bachmann M; Hölzer B; Seibert FS; Rohn BJ; Bauer F; Witzke O; Dittmer U; Bachmann M; Yilmaz S; Dittmer R; Schneppenheim S; Babel N; Budde U; Westhoff TH
    Crit Care Med; 2021 May; 49(5):e512-e520. PubMed ID: 33591004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.
    Philippe A; Gendron N; Bory O; Beauvais A; Mirault T; Planquette B; Sanchez O; Diehl JL; Chocron R; Smadja DM
    Angiogenesis; 2021 Aug; 24(3):407-411. PubMed ID: 33974165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.
    Huisman A; Beun R; Sikma M; Westerink J; Kusadasi N
    Int J Lab Hematol; 2020 Oct; 42(5):e211-e212. PubMed ID: 32441844
    [No Abstract]   [Full Text] [Related]  

  • 12. Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU.
    De Jongh R; Ninivaggi M; Mesotten D; Bai C; Marcus B; Huskens D; Stragier H; Miszta A; Verbruggen J; de Laat-Kremers RMW; Grieten J; de Laat B
    Blood Coagul Fibrinolysis; 2021 Jun; 32(4):290-293. PubMed ID: 33443932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study.
    De Cristofaro R; Liuzzo G; Sacco M; Lancellotti S; Pedicino D; Andreotti F
    Blood Coagul Fibrinolysis; 2021 Jun; 32(4):285-289. PubMed ID: 33443926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.
    Russell RT; McDaniel JK; Cao W; Shroyer M; Wagener BM; Zheng XL; Pittet JF
    Thromb Haemost; 2018 Apr; 118(4):676-687. PubMed ID: 29618154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.
    Bazzan M; Montaruli B; Sciascia S; Cosseddu D; Norbiato C; Roccatello D
    Intern Emerg Med; 2020 Aug; 15(5):861-863. PubMed ID: 32557383
    [No Abstract]   [Full Text] [Related]  

  • 17. Invited commentary to: ADAMTS13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19 by Tiffany Pascreau et al. Letter to the Editors-in-Chief, Thrombosis Research.
    Lämmle B; Rossmann H
    Thromb Res; 2021 Aug; 204():141-142. PubMed ID: 33678420
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma ADAMTS13, von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome.
    Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Tsuda K; Kondo M; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):622-630. PubMed ID: 26759371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.
    Sonneveld MA; Franco OH; Ikram MA; Hofman A; Kavousi M; de Maat MP; Leebeek FW
    Arterioscler Thromb Vasc Biol; 2016 Dec; 36(12):2446-2451. PubMed ID: 27737864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage.
    Kumar M; Cao W; McDaniel JK; Pham HP; Raju D; Nawalinski K; Frangos S; Kung D; Zager E; Kasner SE; Levine JM; Zheng XL
    Thromb Haemost; 2017 Apr; 117(4):691-699. PubMed ID: 28102428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.